Vorapaxar + Placebo + Aspirin + Clopidogrel
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerosis
Conditions
Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
Trial Timeline
Dec 1, 2006 → Oct 1, 2007
NCT ID
NCT00684203About Vorapaxar + Placebo + Aspirin + Clopidogrel
Vorapaxar + Placebo + Aspirin + Clopidogrel is a phase 2 stage product being developed by Merck for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00684203. Target conditions include Atherosclerosis, Myocardial Ischemia, Myocardial Infarction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00684203 | Phase 2 | Completed |
Competing Products
20 competing products in Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Olmesartan medoxomil + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Pactimibe sulfate | Daiichi Sankyo | Phase 2/3 | 65 |
| Pactimibe | Daiichi Sankyo | Phase 2 | 52 |
| Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin | Daiichi Sankyo | Phase 3 | 77 |
| Micronized 17B-estradiol | Johnson & Johnson | Phase 2/3 | 65 |
| Rosuvastatin + placebo + aspirin + placebo | AstraZeneca | Approved | 85 |
| Rosuvastatin + Placebo | AstraZeneca | Approved | 85 |
| rosuvastatin + placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| lovastatin | Merck | Phase 2/3 | 65 |
| Ezetimibe + Placebo | Merck | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Niaspan | Merck | Pre-clinical | 23 |
| MK0633 | Merck | Phase 2 | 52 |